U.S. Stem Cell, Inc. (USRM)
OTCMKTS: USRM · Delayed Price · USD
0.0001
0.00 (0.00%)
Apr 24, 2024, 3:46 PM EDT - Market closed
U.S. Stem Cell Revenue
U.S. Stem Cell had revenue of $19.97K in the twelve months ending September 30, 2023, down -76.68% year-over-year. In the year 2022, U.S. Stem Cell had annual revenue of $82.05K, a decrease of -59.13%.
Revenue (ttm)
$19.97K
Revenue Growth
-76.68%
P/S Ratio
3.21
Revenue / Employee
n/a
Employees
n/a
Market Cap
64.15K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 82.05K | -118.70K | -59.13% |
Dec 31, 2021 | 200.75K | -76.34K | -27.55% |
Dec 31, 2020 | 277.09K | -2.80M | -90.98% |
Dec 31, 2019 | 3.07M | -3.63M | -54.15% |
Dec 31, 2018 | 6.70M | 1.18M | 21.38% |
Dec 31, 2017 | 5.52M | 2.44M | 79.05% |
Dec 31, 2016 | 3.08M | 892.08K | 40.71% |
Dec 31, 2015 | 2.19M | 135.35K | 6.58% |
Dec 31, 2014 | 2.06M | 1.96M | 2,039.60% |
Dec 31, 2013 | 96.09K | 34.98K | 57.24% |
Dec 31, 2012 | 61.11K | 43.63K | 249.69% |
Dec 31, 2011 | 17.48K | -28.91K | -62.32% |
Dec 31, 2010 | 46.38K | -313.42K | -87.11% |
Dec 31, 2009 | 359.80K | 302.75K | 530.66% |
Dec 31, 2008 | 57.05K | -255.76K | -81.76% |
Dec 31, 2007 | 312.81K | 207.31K | 196.49% |
Dec 31, 2006 | 105.50K | -29.85K | -22.05% |
Dec 31, 2005 | 135.35K | 49.35K | 57.38% |
Dec 31, 2004 | 86.00K | 40.00K | 86.96% |
Dec 31, 2003 | 46.00K | 44.00K | 2,200.00% |
Dec 31, 2002 | 2.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |